Dycom Industries Inc. (DY)
Shares of DY soared to reach a new 52-week high in after-hours trading Tuesday as the company delivered stronger-than-expected quarterly financial results.
For its third quarter fiscal 2015, DY posted contract revenues of $492.4 million, a 15.5% increase year over year, and net income of $20.3 million, or $0.58 per diluted share, compared to net income of $7.9 million, or $0.23 per diluted share in the same quarter the prior year, topping the Capital IQ Consensus Estimate of $0.38 earnings per share on revenues of $468.36 million for the period.
According to its business outlook for the fourth quarter fiscal 2015, DY expects total revenue to be in the range $550 million to $570 million and diluted earnings per share to range from $0.74 to $0.82, also exceeding the Capital IQ Consensus Estimate of $0.58 earnings per share on revenues of $521.95 million for the next reported period.
DY is a leading provider of specialty contracting services throughout the United States and in Canada.
More about Dycom Industries Inc. at www.dycomind.com
**
Achillion Pharmaceuticals, Inc. (ACHN)
After the closing bell on Tuesday, ACHN announced an agreement with Janssen Pharmaceuticals, Inc., one of the Janssen Pharmaceutical Companies of Johnson & Johnson (JNJ), to develop and commercialize one or more of ACHN's lead hepatitis C virus (HCV) assets, including ACH-3102, ACH-3422, and sovaprevir.
Under the terms of the agreement, which is subject to customary closing conditions, ACHN will grant Janssen an exclusive, worldwide license to develop and, upon regulatory approval, commercialize HCV products and regimens containing one or more of its HCV assets.
According to ACHN, the deal calls for up to $1.1 billion in potential development, regulatory and sales milestone payments and a separate equity investment (JJDC Inc., the venture capital subsidiary of Johnson & Johnson, will invest $225 million in ACHN in return for about 18.4 million unregistered shares at $12.25 per share)
ACHN, a biopharmaceutical company, focuses on developing combination therapies for the treatment of chronic hepatitis C (HCV) infection and drug-resistant bacterial infections.
More about Achillion Pharmaceuticals, Inc. at www.achillion.com
**
Crown Equity Holdings Inc. (OTCPK:CRWE)
The company is currently developing its CRWE Network ( www.CRWE-PR.com ), a growing network of community targeted sites.
It has recently included the City of Artesia, CA ( www.artesia.crwe-pr.com ) into the CRWE Network.
Artesia is located in southeast Los Angeles County, California. It is surrounded on the west, south, and east sides by Cerritos, with Norwalk to the north.
The City of Artesia had an estimated population in 2013 (U.S. Census Bureau) of 16,736, and represents an important marketplace for the CRWE Network, which business model is based on selling advertising to businesses targeting both locally and nationally
The CRWE Network has reached the 1487th community website in the U.S. and includes coverage in the states of California, Mississippi, Michigan, Florida, Nevada and New York, as well as across 10 provinces in Canada.
The company's CRWE Real Estate ( www.CRWERealEstate.com ) is expected to be integrated in all the CRWE Network. It will allow people to submit their listings for exposure to visitors searching for homes.
CRWE provides marketing solutions that boost customer awareness and merchant visibility on the Internet.
More about Crown Equity Holdings Inc. at www.crownequityholdings.com
**
Disclaimer: CRWE-PR Finance is not a registered investment adviser. This material is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities. Investors should always conduct their own due diligence with any potential investment, with independent research and other professional advice. Read Full Disclaimer at CRWE-PR Finance www.finance.crwe-pr.com/disclaimer